Last reviewed · How we verify
ABEQUOLIXRON
Abequolixron is being studied with Durvalumab in a small lung cancer clinical trial.
Abequolixron is a drug being investigated in lung cancer treatment. It is part of a Phase 1 clinical trial evaluating its use in combination with Durvalumab. The trial included a single patient.
At a glance
| Generic name | ABEQUOLIXRON |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
The provided text does not contain information about the mechanism of action of Abequolixron. Therefore, a plain English explanation cannot be generated from the source data.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABEQUOLIXRON CI brief — competitive landscape report
- ABEQUOLIXRON updates RSS · CI watch RSS
- portfolio CI